Financials data is unavailable for this security.
View more
Year on year CSL Ltd had little change in net income (from 2.25bn to 2.19bn) despite revenues that grew 26.02% from 10.56bn to 13.31bn. A contributing factor has been an increase in the cost of goods sold as a percent of sales from 45.73% to 48.58%.
| Gross margin | 51.57% |
|---|---|
| Net profit margin | 17.80% |
| Operating margin | 25.02% |
| Return on assets | 6.94% |
|---|---|
| Return on equity | 15.05% |
| Return on investment | 8.48% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at CSL Ltd fell by 8.83bn. However, the company earned 2.60bn from its operations for a Cash Flow Margin of 19.54%. In addition the company generated 456.00m cash from financing while 11.84bn was spent on investing.
| Cash flow per share | 10.85 |
|---|---|
| Price/Cash flow per share | 25.65 |
| Book value per share | 54.83 |
|---|---|
| Tangible book value per share | 2.27 |
More ▼
Balance sheet in USDView more
| Current ratio | 2.15 |
|---|---|
| Quick ratio | 0.9708 |
| Total debt/total equity | 0.7048 |
|---|---|
| Total debt/total capital | 0.3872 |
More ▼
Growth rates in USD
Year on year, growth in dividends per share increased 10.20% while earnings per share excluding extraordinary items fell by -5.74%. The positive trend in dividend payments is noteworthy since very few companies in the Biotechnology & Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth is in-line with the industry average relative to its peers, while earnings per share growth is below the industry average.
| Div yield(5 year avg) | 1.16% |
|---|---|
| Div growth rate (5 year) | 7.44% |
| Payout ratio (TTM) | 48.47% |
| EPS growth(5 years) | 3.55 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 16.40 |
More ▼
